ASH 2024: Abstract Recommendations From Dr. Rafael Fonseca

Dr. Rafael Fonseca, Getz Family Professor of Cancer and Professor of Medicine at the Mayo Clinic in Phoenix, Arizona, and Editor-in-Chief of PracticeUpdate Oncology, recommends the following abstracts being presented at this year’s ASH Annual Meeting taking place December 7–10, 2024, in San Diego, California, and online.

Monday, December 9, 2024; 10:30 AM–12:00 PM PST
Oral and Poster Abstracts
Session 654 — Pharmacologic Therapies

769 Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7). H Goldschmidt, U Bertsch, E Poze, et al

773 Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study. MA Dimopoulos, PM Voorhees, F Schjesvold, et al

Monday, December 9, 2024; 4:30 PM–6:00 PM PST
Oral and Poster Abstracts
Session 655 — Multiple Myeloma: Cellular Therapies

1031 Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial. CL Freeman, B Dhakal, G Kaur, et al